Primary ADT Does Not Extend Low-Risk Prostate Cancer Survival

Androgen deprivation therapy for the treatment of men with low-risk prostate cancer is not supported by long-term study data...

ESMO members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.